Cadila Healthcare’s arm receives ANDA approval for Dextroamphetamine IR Tabs

31 Mar 2016 Evaluate

Cadila Healthcare’s Nether Pharmaceuticals has received its first ANDA approval from the USFDA to market Dextroamphetamine IR Tabs. Nether Pharmaceuticals is a subsidiary of Zydus Pharmaceuticals USA. The drug falls in the CNS stimulant segment and is the first product to be developed by the R&D team at Nesher. The drug will be produced at the manufacturing facility based at St. Louis, Missouri, USA. The estimated sale for Dextroamphetamine IR Tabs is $40.6 mn as per IMS.

Nesher has considerable expertise in niche therapies which have development or production barriers, such as controlled release medications or DEA-controlled substances, which otherwise cannot be imported.

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies. It is the only Indian pharma company to launch its own patented NCE - Lipaglyn, the world’s first drug to be approved for the treatment of diabetic dyslipidemia.

Zydus Lifesciences Share Price

875.05 -6.05 (-0.69%)
20-Jan-2026 12:29 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1639.70
Dr. Reddys Lab 1184.30
Cipla 1378.30
Zydus Lifesciences 875.05
Lupin 2163.00
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×